ArticleGland surgery2023
The clinical characteristics of pancreatic colloid carcinoma and the development and validation of its cancer-specific survival prediction nomogram.
Article in Gland surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Colloid Carcinoma of the Pancreas: A Distinct and Less Aggressive Entity in the Spectrum of Pancreatic Malignancies.Annals of surgical oncology · 2026Article
- Establishment of nomogram of early death in elderly pancreatic cancer patients with liver metastasis.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic colloid carcinoma (CC) is a subtype of pancreatic ductal adenocarcinoma (DAC) with low incidence but high malignancy. Unfortunately, there is no consensus regarding the clinical features and prognostic factors associated with CC, and the prognosis is unpredictable. We aimed to assess the clinicopathological characteristics of this rare disease and develop a nomogram for predicting cancer-specific survival (CSS) in CC. Methods: We gathered comprehensive clinicopathological data from the Surveillance, Epidemiology, and End Results (SEER) database on 17,617 patients with DAC and 561 individuals with CC. Kaplan-Meier was used to plot each survival curve. Subsequently, we split the 561 patients with CC in a 7:3 split ratio between an internal training cohort (n=393) and an external validation cohort (n=168). The independent prognostic factors for CC patients in the training cohort were discovered using univariate and multivariate Cox regression analyses, and a nomogram was created. We assessed the nomogram's performance by using the concordance index (C-index), the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). Results: The median for follow-up of CC patients was 15 months (range: 1-163 months), and the 1-, 3-, and 5-year CSS were 58.4%, 30.2% and 22.6%. For CC patients in the training cohort, age [hazard ratio (HR) =1.29; 95% confidence interval (CI): 1.00-1.65], sex (HR =0.64; 95% CI: 0.51-0.81), T3 stage (HR =2.21; 95% CI: 1.26-3.88), T4 stage (HR =2.76; 95% CI: 1.47-5.18), N1 stage (HR =1.29; 95% CI: 1.02-1.63), M1 stage (HR =1.60; 95% CI: 1.17-2.18), surgery (HR =0.30; 95% CI: 0.22-0.42), and radiotherapy (HR =0.76; 95% CI: 0.58-1.01) were the main predictors of the nomogram. The C-indexes of the training cohort and the validation cohort were 0.734 and 0.732, respectively. The 1-, 3-, and 5-year AUC values of the nomogram were predicted to be 0.827, 0.816, and 0.831 in the training cohort, 0.801, 0.841, and 0.835 in the validation cohort, respectively. Conclusions: Based on several clinical features, we established the first predictive model of CC. This nomogram could be used to guide treatment decisions in patients with CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.